Gold Colloid, Co., a point-of-care (POC) test development company, and Claremont BioSolutions LLC, a life science tools company offering novel rapid sample preparation and test development products, today announced a distribution agreement for Gold Colloid’s gold nanoparticles.
La Mesa, CA – September 8, 2023 – Gold Colloid, Co., a point-of-care (POC) test development company, and Claremont BioSolutions LLC, a life science tools company offering novel rapid sample preparation and test development products, today announced a distribution agreement for Gold Colloid’s gold nanoparticles.
The agreement will allow Claremont BioSolutions to distribute Gold Colloid’s gold nanoparticles to its customers in the life sciences, medical, and environmental testing markets. Gold nanoparticles are used in a variety of applications, including diagnostics, biosensing, and bioimaging.
“We are excited to partner with Claremont BioSolutions to distribute our gold nanoparticles,” said Daniel Levenson, President of Gold Colloid. “Claremont BioSolutions has a strong track record of success in the life sciences market, and we believe this partnership will help us to reach a wider audience of customers.”
“We are pleased to partner with Gold Colloid to distribute their gold nanoparticles,” said Dr. Robert Doebler, President of Claremont BioSolutions. “We have been using Gold Colloid Company’s high-quality 40nm gold nanoparticles for over 5 years. We feel this partnership will help us to meet the needs of our many R&D customers who appreciate highly monodisperse gold nanoparticles in lateral flow assay development.”
Daniel Levenson, President, Gold Colloid, Co. can be reached at d.levenson@goldcolloid.com
